HR Execs on the Move

Quanterix

www.quanterix.com

 
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company`s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix` technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.quanterix.com
  • 900 Middlesex Turnpike
    Billerica, MA USA 01821
  • Phone: 617.301.9400

Executives

Name Title Contact Details
Austin Olson
Finance Manager Profile
Vandana Sriram
Chief Financial Officer Profile
Jennifer Liberi
Director Global Commercial Enablement and Learning Profile
Kishore Malyavantham
Senior Director, Assay Development, @Accelerator and Clinical Services Profile
Nuno Goncalves
Vice President Of Product Management Profile

Similar Companies

Protea Biosciences

Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brampton Cosmetic Surgery

Brampton Cosmetic Surgery is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Imara

Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.

On Target Laboratories

Our illuminating molecules enhances the doctors ability to see disease tissue clearly improving their ability to treat cancer, autoimmune and other diseases.

http://www.katumbas.com/

http://www.katumbas.com/ is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.